# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Joel Beatty initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Pr...
JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintain...